First Director Named for NHGRI’S New Division of Genomics and Society
News Nov 15, 2013
Lawrence C. Brody, Ph.D. has been selected to be the first director of the newly established Division of Genomics and Society at the National Human Genome Research Institute (NHGRI).
Dr. Brody is currently chief of the Genome Technology Branch within NHGRI’s intramural research program, and the chief scientific officer of the trans-NIH Center for Inherited Disease Research. NHGRI is one of the 27 institutes and centers that make up the National Institutes of Health.
Dr. Brody’s expertise and interests are wide-ranging, from human genetics and genomics to the public understanding of science. As a bench scientist, he played an instrumental role in early and important discoveries about the BRCA1 gene, which is responsible for a hereditary form of breast cancer.
His research efforts have regularly included studying the practical implications of genomic advances. For example, Dr. Brody was a co-architect of the NHGRI Multiplex Initiative, an innovative project that aimed to better understand how the general public comprehends and reacts to personal genetic testing results.
Dr. Brody has also invested a considerable amount of his professional efforts to addressing the broader societal issues relevant to contemporary genomics research. He has worked on several projects related to genomics, society, and minority populations and, most recently, he served as a key developer of the public exhibition, Genome: Unlocking Life’s Code, which opened in June at the Smithsonian Institution’s National Museum of Natural History.
Moreover, on multiple occasions, he worked closely with the U.S. Solicitor General in the drafting and editing of legal briefs and in the preparation of oral arguments for the gene patenting case that went before the U.S. Supreme Court earlier this year.
“Dr. Brody brings an extraordinary and diverse body of accomplishments and expertise to lead this newly created division,” said NHGRI Director Eric D. Green, M.D., Ph.D. “His perspective as a bench scientist combined with a demonstrated long-term interest in the intersection of science and society makes him uniquely qualified to lead this critical part of NHGRI’s research program.”
The Division of Genomics and Society was established in 2012 as part of an institute-wide reorganization. It is one of four divisions that make up the institute’s extramural research program.
This new division is now responsible for an expanded program related to the many societal issues relevant to genomics research and genomic advances, incorporating and extending the activities of NHGRI’s Ethical, Legal and Social Implications (ELSI) research program.
The latter was established in 1990 as part of the Human Genome Project and aims to pursue multidisciplinary research and training designed to explore the impact of genomics on society.
“It is an exciting time for genetics and genomics, but with that comes the responsibility to examine and address the many important societal implications of these research advances. With improvements in technology as the driving force, genomics can increasingly be used in clinical settings in a way that was simply not possible a decade ago,” Dr. Brody said. “Because genomics is moving closer to our daily lives, we need to better understand its societal impact. Issues such as consent, privacy, and access to genomic information will continue to grow in importance. We need to increasingly pursue research to understand these issues and to engage relevant stakeholders, including the general public, in the discussions.”
Several large NHGRI programs incorporate elements of ELSI research into their studies, including the Clinical Sequencing Exploratory Research program, the Implementing Genomics into Clinical Practice Network, and the Genomic Sequencing and Newborn Screening Disorders program.
Dr. Brody would like to eventually see similar ELSI research programs be implemented by other institutes and centers across NIH. He also sees several related areas for potential research focus, including exploring a legal framework for genetic/genomic testing and examining how advances in genomic technologies affect the economics of medical practice.
Dr. Brody received a B.S. in biology from the Pennsylvania State University, University Park, in 1982, and a Ph.D. in human genetics from Johns Hopkins University, Baltimore, in 1991. He was a Howard Hughes Medical Institute (HHMI) Research Associate from 1990 to 1993 and an HHMI postdoctoral fellow at Johns Hopkins University and the University of Michigan, Ann Arbor, during that time.
He joined NHGRI in 1993 as a senior staff fellow, and became senior investigator and head of the Molecular Pathogenesis Section in the Genome Technology Branch in 2001. Dr. Brody has been chief of that branch since 2010, and the chief scientific officer at the trans-NIH Center for Inherited Disease Research since 2006.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE